PARP1 and breast carcinoma: Eliminating the need for chemotherapy for more gBRCAm carriers with breast cancer, expanding the population of patients with breast cancer who can benefit from a PARP inhibitor and reducing cancer risk for gBRCAm carriers so that prophylactic surgeries are no longer needed are among the dreams of the future.